Dihexa vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
Also: PE22-28, Spadin Analog
A synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Dihexa | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa activates hepatocyte growth factor (HGF) signaling through the c-Met receptor. This promotes dendritic spine formation, enhances synaptic connections, and supports neuronal survival. Crosses blood-brain barrier orally. | PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore domain potassium channel highly expressed in the brain. TREK-1 inhibition increases neuronal excitability and enhances serotonergic and noradrenergic neurotransmission. This mechanism is distinct from traditional SSRIs and produces rapid-onset antidepressant effects in preclinical studies. |
| Common Dosing | 5-20 mg oral or sublingual daily Once daily, effects can last up to 10 days | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Oral, sublingual, or intranasal | Intranasal or subcutaneous injection |
| Typical Duration | Cycles of 2-4 weeks | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Animal studies show remarkable cognitive enhancement and reversal of scopolamine-induced memory deficits. Research demonstrates increased dendritic spine density. Limited human data but significant interest in nootropic community. | Animal studies demonstrate significant antidepressant and anxiolytic effects within days of administration (faster than traditional SSRIs which take weeks). PE-22-28 shows improved stability compared to full Spadin while maintaining efficacy. Research indicates potential for treatment-resistant depression. No human clinical trials conducted yet. |
Frequently Asked Questions: Dihexa vs PE-22-28
What is the difference between Dihexa and PE-22-28?
Dihexa is a cognitive peptide that a potent cognitive-enhancing peptide derived from angiotensin iv. reported to be 10 million times more potent than bdnf at promoting synaptogenesis. PE-22-28 is a cognitive peptide that a synthetic heptapeptide (7 amino acids) derived from spadin, a naturally occurring antidepressant peptide. pe-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of spadin. works by blocking trek-1 potassium channels in the brain. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.